Samotolisib in treating patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic disorders with TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial). This evidence concerns the gene MTOR and tuberous sclerosis.